| XLS |
|
|
|
|
|
|
|
€ million |
Q3 – 2013 |
Q3 – 2012 |
Jan.–Sept. |
Jan.–Sept. |
|
Sales |
2,659.5 |
2,721.7 |
8,063.8 |
8,028.7 |
|
Royalty, license and commission income |
92.3 |
119.4 |
289.6 |
309.4 |
|
Total revenues |
2,751.8 |
2,841.0 |
8,353.4 |
8,338.1 |
|
|
|
|
|
|
|
Cost of sales |
–723.4 |
–787.6 |
–2,215.3 |
–2,344.1 |
|
Gross profit |
2,028.4 |
2,053.4 |
6,138.0 |
5,994.0 |
|
|
|
|
|
|
|
Marketing and selling expenses |
–560.1 |
–598.0 |
–1,744.7 |
–1,801.8 |
|
Royalty, license and commission expenses |
–144.4 |
–161.6 |
–437.2 |
–433.4 |
|
Administration expenses |
–136.7 |
–141.6 |
–407.0 |
–420.6 |
|
Other operating expenses and income |
–128.4 |
–245.1 |
–428.2 |
–878.4 |
|
Research and development |
–379.3 |
–370.8 |
–1,159.1 |
–1,156.5 |
|
Amortization of intangible assets |
–197.7 |
–218.2 |
–616.6 |
–651.8 |
|
Investment result |
– |
– |
1.4 |
0.5 |
|
Operating result (EBIT) |
481.8 |
318.1 |
1,346.6 |
651.9 |
|
|
|
|
|
|
|
Financial result |
–51.9 |
–58.2 |
–159.1 |
–193.9 |
|
Profit before income tax |
430.0 |
260.0 |
1,187.5 |
458.0 |
|
|
|
|
|
|
|
Income tax |
–87.4 |
–71.3 |
–259.9 |
–154.7 |
|
Profit after tax |
342.5 |
188.7 |
927.6 |
303.3 |
|
|
|
|
|
|
|
of which attributable to Merck KGaA shareholders (net income) |
339.6 |
185.5 |
921.6 |
294.9 |
|
of which non-controlling interest |
3.0 |
3.2 |
6.0 |
8.3 |
|
|
|
|
|
|
|
Earnings per share (in €) |
|
|
|
|
|
basic |
1.56 |
0.85 |
4.24 |
1.36 |
|
diluted |
1.56 |
0.85 |
4.24 |
1.36 |

search hit 11